Mezatrin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mezatrin

Quick Facts

Property Description
Active ingredient Azithromycin
Form Tablet, Oral Suspension, IV Solution
Pharmacological class Macrolide Antibiotic (Azalide)
General purpose Clearing bacterial infections
Origin Semi-synthetic

What Type of Medicine Is Mezatrin?

Mezatrin is a trademarked prescription medicine based on the active ingredient Azithromycin. Azithromycin is classified as a macrolide antibiotic, specifically categorized as an azalide, a distinct subclass of macrolides. This compound is of semi-synthetic origin, manufactured by chemically altering the structure of the naturally occurring macrolide, Erythromycin, to enhance its physiological handling and efficacy.

Composition, Form, and General Purpose

Azithromycin is a single-component anti-infective agent supplied in several different dosage forms for patient use, including film-coated tablets and powder for oral suspension for the oral route, with additional solutions available for intravenous injection. As a broad-spectrum agent, its general therapeutic purpose is to clear up bacterial infections, such as those impacting the respiratory system, by halting the growth and reproduction of susceptible bacteria.

Key Structural Difference and Benefit

The chemical modification that defines Azithromycin granted it certain characteristics, including stability in the presence of stomach acid and an ability to accumulate in body tissues. This distribution profile and its slow metabolic clearance result in a prolonged half-life, which supports the therapeutic substance remaining at the site of infection for an extended duration. This sustained presence is a clinically relevant characteristic that often allows for simplified, shorter courses of therapy compared to older antibiotics.

What side effects are possible with Mezatrin?

Possible Side Effects and Safety Information

The safety profile of Mezatrin (Azithromycin) is officially documented by government health authorities, classifying adverse reactions primarily by frequency and the affected body system. This section details the officially listed risks and safety considerations.

Frequency and System-Organ Classifications

The most common side effects reported in regulatory documents primarily involve the gastrointestinal system, including diarrhea, nausea, and abdominal pain. Uncommon reactions may affect the nervous system (e.g., dizziness) and the skin (e.g., rash, photosensitivity). Reactions classified as rare or of not known frequency relate to serious, post-marketing events.

Documented Serious Adverse Reactions

Official labeling highlights several serious adverse reactions. Azithromycin may cause prolongation of the QT interval, which carries a rare risk of a severe heart rhythm abnormality called Torsades de Pointes and sudden cardiovascular death. The medication is also associated with rare but potentially fatal hepatic failure, as well as severe allergic reactions, including anaphylaxis and skin conditions like Stevens-Johnson Syndrome (SJS). Clostridium difficile-Associated Diarrhea (CDAD) is also a documented gastrointestinal risk.

Safety Considerations and Restrictions

Safety notes specify considerations for certain populations and conditions. The medication is officially contraindicated for patients with a history of cholestatic jaundice or liver dysfunction related to prior azithromycin use. Caution is advised for patients with pre-existing proarrhythmic conditions, such as known QT prolongation. Specific populations noted for increased risk include neonates (due to a reported risk of Infantile Hypertrophic Pyloric Stenosis, IHPS), older adults, and women (due to increased susceptibility to QT interval effects).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosing on Mezatrin can lead to severe and potentially life-threatening effects, primarily involving the cardiovascular and gastrointestinal systems. Symptoms of an overdose may include pronounced gastrointestinal distress, such as severe nausea, vomiting, diarrhea, and stomach pain.

Of greater concern are symptoms related to the heart, which can manifest as a dangerous change in heartbeat or heart rhythm. These signs include chest pain, dizziness, a fast or irregular heartbeat (palpitations), feeling faint or lightheaded, falls, and breathing problems. The most critical risk is a potentially fatal irregular heart rhythm, known as torsades de pointes.

Immediate medical attention is required if any of the following symptoms occur while taking Mezatrin: an irregular heartbeat, shortness of breath, severe dizziness, or fainting. Individuals with pre-existing heart conditions, a slower than normal heart rate, or low levels of potassium or magnesium may be at higher risk for these serious cardiac events.

In the event of a suspected overdose, the medication should be stopped immediately. Do not attempt to induce vomiting or ingest substances to counteract the effects. Contact your local poison control center or seek emergency medical care right away.

Therapeutic Uses of Mezatrin

What Mezatrin Treats: Main Uses and Benefits

Mezatrin (Azithromycin) is a prescription antibiotic commonly used across several domains to manage bacterial infections and the resulting symptomatic discomfort, generally offering the key benefit of supporting a simplified treatment duration. This medication is utilized to help with bacterial infections in multiple body systems.


Quick Fact: Therapeutic Support

Domain Symptom Axis Managed
Acute Infection Symptoms related to inflammatory or irritative states and acute pain
Chronic Management Symptoms that become more disruptive during flare-ups

Addressing Acute Respiratory and Ear Infections

This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns from conditions presenting with systemic or localized discomfort, such as respiratory or ear infections. It is used when groups of symptoms cluster into patterns of severe cough, chest congestion, fever, or acute ear pain, providing supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

Applied for Managing Sexually Transmitted and Skin Infections

Mezatrin is relevant when supportive symptom management is appropriate for acute genitourinary tract infections and for managing uncomplicated bacterial infections of the skin. The medication helps address groups of symptoms such as localized discharge, swelling, or non-healing sores, contributing to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

Supportive Management of Chronic Airway Exacerbations

The medication is commonly used when short-term symptomatic assistance is needed in patients with underlying chronic conditions, such as COPD. It is applied during phases when symptoms become more noticeable due to acute exacerbations, and supports the patient during difficult episodes by easing distress, which may assist with maintaining functional stability and reducing the frequency of future symptomatic flare-ups.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Mezatrin (Azithromycin) is an antibiotic medication that should only be used by patients whose infection is confirmed or strongly suspected to be caused by susceptible bacteria. Official regulatory documents define specific populations who are prohibited from using this medicine and others for whom its use is strictly limited.

Eligibility Classification Population Restriction
Contraindicated Patients with a known hypersensitivity or severe allergic reaction to azithromycin, erythromycin, or any macrolide or ketolide drug.
Contraindicated Patients with a history of cholestatic jaundice or liver dysfunction that was previously associated with the use of azithromycin.

Age-Related Eligibility

Safety and effectiveness of the oral formulations have not been established for the treatment of patients under six months of age for certain infections, such as acute otitis media or community-acquired pneumonia. For pharyngitis/tonsillitis, use is not established for patients under two years of age.

Condition-Specific Limitations

Mezatrin is not recommended for patients with pneumonia who are deemed inappropriate for oral therapy due to the moderate to severe nature of their illness or the presence of specific risk factors (e.g., suspected bacteremia or a need for hospitalization). Caution is advised for patients with severe renal impairment or pre-existing cardiac conditions associated with QT prolongation.

What should I know about interactions with other medicines?

Mezatrin (Azithromycin) must not be co-administered with Ergotamine derivatives due to the class-wide, theoretical risk of acute ergotism, which is a formal regulatory prohibition. The drug’s official profile documents several significant pharmacokinetic and pharmacodynamic interactions requiring attention.

Co-administration with other QT-prolonging medicines, such as certain antiarrhythmics, increases the risk of serious ventricular arrhythmias, including Torsades de Pointes. This is an official pharmacodynamic interaction.

Several specific medicines affect or are affected by Azithromycin exposure. Nelfinavir is documented to cause a significant increase in Azithromycin serum concentrations. Conversely, the use of Warfarin may potentiate its effects, requiring careful monitoring for increased coagulation times. Drugs such as Digoxin and Phenytoin should also be closely monitored based on potential interactions observed with other macrolide antibiotics.

A mandatory administration-timing rule applies to antacids containing Aluminum or Magnesium Hydroxide. These products reduce the peak plasma concentration ( C max) of Azithromycin and must therefore be taken at least one hour before or two hours after Azithromycin. Unlike some older antibiotics, Azithromycin is officially noted as not interacting significantly with the hepatic CYP450 system. Population notes caution that elderly patients may be more susceptible to the drug’s QT interval effects.

Mechanism of Action

How Mezatrin Works


Targeted Inhibition of Bacterial Protein Synthesis

Mezatrin (Azithromycin) targets the 50 S ribosomal subunit inside susceptible bacteria, physically blocking the peptide exit tunnel to prevent protein chain elongation. This action halts the production of proteins essential for bacterial growth, resulting in a bacteriostatic effect that limits pathogen proliferation and allows for the reduction of the bacterial load by host defense mechanisms.


Enhanced Tissue Concentration and Delivery

The drug's mechanism is supported by its ability to accumulate rapidly within the body's tissues and host immune cells (phagocytes), often reaching concentrations far exceeding those in the bloodstream. This intracellular accumulation allows the immune cells to act as carriers, delivering high concentrations of the drug directly to the site of infection, supporting prolonged exposure of the pathogen to the active compound against both extracellular and intracellular pathogens.


Modulation of Local Inflammatory Responses

Azithromycin also engages in immunomodulation, a secondary mechanism independent of its antibacterial action. It works within host cells to suppress key signaling pathways, such as NF-kappa B, which drives inflammation. This modulation reduces the release of excessive pro-inflammatory mediators like IL-8, contributing to the physiological consequence of dampened tissue inflammation.

Dosage and Administration Information

How to Use Mezatrin: Official Administration Guidelines

Mezatrin (Azithromycin) administration is defined by guidelines concerning route, dosage, frequency, and duration. This structure ensures the medicine is used according to its specifications for various approved indications.


Administration Protocol Overview

Route of Administration Dosing Schedule (Adults) Special Conditions
Oral (Tablets, Suspension) 3-Day Course: 500 mg once daily for 3 days. 5-Day Course: 500 mg on Day 1, then 250 mg once daily on Days 2–5. May be taken with or without food.
Intravenous (IV) 500 mg once daily for 1 to 2 days, followed by oral therapy to complete the course. Must be administered as a slow infusion over at least 60 minutes; not to be given as a bolus or intramuscular injection.

Procedural and Population Rules

Azithromycin dosing is based on these short, sequential courses and is designed for once-daily frequency. Pediatric dosing (for patients age 6 months and older) is determined by body weight, while older adults generally receive the same dose as other adults. Patients with mild to moderate renal or hepatic impairment typically do not require dosage adjustment; however, the medicine is not recommended in cases of severe hepatic disease.

For the intravenous route, the 500 mg powder must be reconstituted and diluted prior to infusion. If a dose is missed, instructions advise taking it immediately, then taking the next dose 24 hours after the belated dose, thereby re-establishing the once-daily schedule. The overall use protocol is defined by this required shift from an initial, sometimes higher, concentration to a standard once-daily maintenance dose over the prescribed duration.

Recent Clinical Evidence

Research evidence / Overview of studies for Mezatrin

Research was conducted exploring Mezatrin in people with ulcerative colitis, which is one of the conditions presenting with cycles of stability and flare-ups. Clinical research exploring this condition was relevant in trials assessing short-term or episodic symptom patterns and used observational settings evaluating daily-life functioning.

The studies conducted during periods of increased symptom activity monitored outcomes linked to inflammatory or irritative states, as well as patient-reported outcomes describing perceived discomfort. Data show patterns related to how symptoms evolved in the observed populations. These results reflect the specific conditions under which they were conducted and findings help contextualize how patients reported their experience during the observed time intervals.


Studies monitored populations living with rheumatoid arthritis, a condition marked by functional limitations and characterized by fluctuating or episodic manifestations. Studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies contributed to the broader evidence landscape by describing how symptoms evolved in the observed populations. Comparative evidence is lacking for certain endpoints, meaning there is limited information available on how Mezatrin compares to all other possible approaches currently available.


Long-term studies and follow-up

The follow-up durations for many studies were limited. Studies monitored responses over defined time intervals, and evidence is limited regarding the sustained effect. Long-term effects are not fully established, meaning there is limited information for long-term outcomes beyond one year. Research is ongoing to help clarify these patterns.


What is still uncertain about Mezatrin

It is important to understand that certainty remains low for certain less common or secondary outcomes observed in the studies. Evidence quality varies across studies, and some smaller studies focusing on very specific patient groups observed findings that were mixed. Research findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain. Further research is ongoing to fill existing research gaps.

Key Studies & References

  1. Ulcerative colitis: management (NICE Guideline NG130)
  2. Rheumatoid arthritis in adults: management (NICE Guideline NG100)

Frequently Asked Questions (FAQ)

Common questions about Mezatrin (FAQ)

Q: Is Mezatrin the same kind of medicine as [similar common drug name]?

A: Official product information classifies Mezatrin (Azithromycin) as a macrolide antibacterial. More specifically, it is an azalide, which is a distinct subclass of macrolide antibiotics. This classification describes its structure and how it works to manage bacterial infections.

Q: How long does the effect of a single dose of Mezatrin last?

A: The active ingredient in Mezatrin has a prolonged half-life, which is the time it takes for half of the drug to be eliminated from the body. Official pharmacokinetic data notes this half-life is around 68 hours (about 2.8 days), which supports its sustained therapeutic presence in the body over the course of treatment.

Q: Can Mezatrin cause tiredness or sleepiness?

A: Official documents list sleepiness (somnolence) as an uncommon side effect that may affect the nervous system. As with any medication, patient experiences can vary, and it's important to be aware of how the medicine is tolerated.

Q: Are there any known food or drink restrictions while on Mezatrin?

A: The official instructions state that the medicine may be taken with or without food. However, antacids containing aluminum or magnesium must be taken at least one to two hours before or after the dose due to the potential for these products to reduce the drug's absorption.

Q: Why is Mezatrin not recommended for children?

A: Regulatory documents indicate that the safety and effectiveness of the oral formulation are not established for infants under a specific age (e.g., under six months) for certain infections. The label also carries a specific warning regarding the rare risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates (newborns).

Q: Is Mezatrin intended for short-term or long-term use?

A: The drug is officially prescribed in short, sequential courses, often lasting 3 or 5 days. Regulatory guidance emphasizes its use should be optimized, which is done to support the minimization of antimicrobial resistance.

Q: Is Mezatrin considered a 'cure' or a treatment for symptoms?

A: The general purpose described in official documents is to clear bacterial infections by halting the growth and reproduction of bacteria, which is known as a bacteriostatic effect. By limiting the pathogen's proliferation, the medicine supports the body’s own clearance mechanisms.

Q: Can Mezatrin be crushed or split?

A: The film-coated tablet form of the medicine is typically designed to be swallowed whole. Official patient information often advises not to cut, break, or chew the tablets, as this may affect how the drug is absorbed or delivered.

Q: How quickly does Mezatrin start working after taking it?

A: Regulatory documents emphasize the drug’s ability to rapidly accumulate in body tissues and at the site of infection, a process which is supported by its prolonged half-life. However, official information does not specify an exact time frame for when a patient can expect to feel clinical improvement.

Q: Does Mezatrin have a risk of addiction?

A: According to the Drug Enforcement Administration (DEA), the medicine is not classified as a controlled substance. Official prescribing information does not associate the drug with a risk of addiction or dependence.

Q: Is Mezatrin known to interact with common pain relievers like ibuprofen?

A: The official interaction profile does not list specific interactions with common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, consultation with a healthcare professional regarding all co-administered medicines is noted.

Q: Can Mezatrin affect my blood pressure?

A: Post-marketing surveillance reports, which collect information on adverse events after a drug is widely used, include reports of both hypotension (low blood pressure) and hypertension (high blood pressure) as adverse reactions of unknown frequency.

Q: Is it okay to drink alcohol while using Mezatrin?

A: Official labels do not list a direct chemical interaction with alcohol. However, consumption of alcohol may worsen common side effects like nausea and diarrhea, or may potentially interfere with recovery from the underlying infection.

Q: What happens if I stop using Mezatrin suddenly?

A: Official instructions advise immediate discontinuation if serious adverse reactions, such as signs of liver problems or severe allergic reactions, occur. Otherwise, completing the full prescribed course is often emphasized to ensure the infection is properly managed and minimize the risk of bacterial resistance.

Q: Does Mezatrin affect birth control pills?

A: Regulatory reviews suggest that macrolide antibiotics generally do not significantly affect the plasma levels of the estrogenic components in oral contraceptives. However, consultation with a prescriber is noted for patients using hormonal birth control.

Q: Is there a generic version of Mezatrin available?

A: Yes, the medicine is a trademarked version of the active ingredient azithromycin. This ingredient is available in a generic form in most markets.

Q: Is Mezatrin safe to use during pregnancy, according to official sources?

A: The official label contains a section on Use in Specific Populations, including Pregnancy, which outlines available data from human and animal studies. This information is used by prescribers to weigh the potential benefits of use against any potential risks during gestation.

Q: Does Mezatrin interact with herbal supplements like St. John's Wort?

A: Regulatory bodies advise that there is not enough information to definitively state the safety of combining the medicine with complementary or herbal remedies. This is because these supplements are not formally tested for interactions in the same way as prescription medicines.

Q: Is it possible to develop a tolerance to the effects of Mezatrin?

A: Official documents emphasize the risk of antimicrobial resistance developing in the target bacteria. This is a situation where the bacteria may adapt over time and no longer be susceptible to the drug's effects.

Q: Is Mezatrin a controlled substance?

A: No, the drug is not classified as a controlled substance by the Drug Enforcement Administration (DEA) or similar international bodies.

Q: Can Mezatrin change my mood?

A: Official labels list psychiatric adverse reactions in post-marketing reports, though they are of unknown frequency. These reactions include reports of aggression, anxiety, and nervousness.

Q: Does the time of day I take Mezatrin matter?

A: Instructions state that the drug is to be taken once daily. While it can be taken anytime with or without food, instructions often recommend consistency in the timing of the dose to support the maintenance of a stable concentration of the drug in the body.

Q: Does taking Mezatrin require regular blood tests?

A: Routine blood tests are not required for all patients. However, the label advises close monitoring when the drug is used with certain drugs like Warfarin. Liver enzyme checks may also be recommended due to the potential for rare hepatic issues.

Q: What regulatory bodies (like the FDA or EMA) have approved Mezatrin?

A: The drug has been approved and reviewed by major international bodies. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are among the regulatory bodies that have provided specific guidance on the use of this medicine.

Q: Has Mezatrin been recalled or withdrawn in any country?

A: Government agencies publish comprehensive, public databases for recalls, market withdrawals, and safety alerts. Patients can check these public resources for the current regulatory status of the product.

Q: Can Mezatrin interact with medicines for diabetes?

A: Official interaction profiles generally do not list specific interactions with common anti-diabetic medications. However, review of all co-administered drugs by a healthcare provider is recommended.

Q: Is Mezatrin known to cause weight gain or loss?

A: Post-marketing surveillance reports list both unusual weight loss and rapid weight gain as adverse reactions. These effects are reported with an unknown frequency.

Q: Can Mezatrin be taken by someone who is breastfeeding?

A: The official label includes a section on Lactation which describes the presence of the drug in human milk. This information is used to help weigh the health and developmental benefits of breastfeeding against any potential risks to the infant.

Q: Do I need a special prescription for Mezatrin?

A: The medicine is classified as a prescription-only medicine (Rx). Since it is not a DEA-scheduled controlled substance, a special prescription form is typically not required, but strict adherence to all existing prescription laws applies.

Q: Are there any documented cases of overdose with Mezatrin?

A: Official prescribing information addresses the signs and symptoms of acute overdose. These can include severe manifestations of gastrointestinal side effects like nausea, vomiting, and diarrhea, and professional care is advised in such cases.

Q: Does smoking affect how Mezatrin works?

A: NIH-sponsored research conducted for certain lung conditions noted an observation where the drug's efficacy was reduced in current smokers compared to ex-smokers in that specific study population.

Q: What is the maximum amount of time research evidence covers for using Mezatrin?

A: Studies monitored responses over defined time intervals, and research data on the sustained effect is limited beyond one year. Follow-up durations for many studies are restricted to shorter periods, and research is ongoing to clarify these long-term patterns.

Q: How is the safety profile of Mezatrin described in official package inserts?

A: The safety profile is officially described by frequency (common, uncommon, rare, or unknown) and is classified by the affected body systems. This description includes the list of all documented serious adverse reactions.

How should Mezatrin be stored and disposed of?

Official Storage and Disposal Profile

The storage requirements for Mezatrin (Azithromycin) are strictly defined by the product's form to ensure stability and efficacy.

Product Form Storage Temperature Stability/Handling
Tablets / Dry Powder Store at controlled room temperature (20 C to 25 C or 68 F to 77 F). Keep in the original, tightly closed container.
Reconstituted Suspension Store below 30 C (86 F) or refrigerate. Must not be frozen. Discard any unused portion after 10 days.

All forms of this medication must be stored out of the sight and reach of children. Unused or expired medicine should be safely disposed of by following official guidelines, such as mixing it with an undesirable substance before placing it in household trash, or using a community drug take-back program. Do not flush the medication down the toilet unless explicitly instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mezatrin found in:

A-Z Index: